EU Business Round-Up: EA Pharma Acquires Drasanvi, Bios Line Attracts Investment, Diapharm Sets Up Swiss Office
Executive Summary
The latest European consumer health business news: France's EA Pharma snaps up Spain's Drasanvi; Italy's Bios Line attracts minority investment; and Diapharm sets up in Switzerland to help device manufacturers.
You may also be interested in...
EA Pharma Enters US And Launches Olyos Group
France's EA Pharma is now operating as part of Olyos Group, alongside Spain’s Drasanvi, Italy’s Stardea and recently-acquired US dietary supplements firm W Group.
Cooper Divests Stardea To France's EA Pharma
Italian nutraceutical player Stardea has changed hands. Following six years of ownership by Cooper Consumer Health, the business has been acquired by France's EA Pharma which is keen to expand its footprint outside of its home market.
Timely Acquisition Keeps Germany's Dermapharm Growing
With its Branded Pharmaceuticals division negatively impacted by the end of the COVID-19 pandemic, the timely acquisition of supplements firm Arkopharma ensured Dermapharm recorded double-digit sales growth in 2023.